Preferred Label : Linaclotide;
NCIt synonyms : [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide; L-Tyrosine, L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-
asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (1-
6), (2- 10), (5- 13)-tris(disulfide);
NCIt definition : A synthetic, fourteen amino acid peptide and agonist of intestinal guanylate cyclase
type C (GC-C), which is structurally related to the guanylin peptide family, with
secretagogue, analgesic and laxative activities. Upon oral administration, linaclotide
binds to and activates GC-C receptors located on the luminal surface of the intestinal
epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate
(cGMP), which is derived from guanosine triphosphate (GTP). cGMP activates the cystic
fibrosis transmembrane conductance regulator (CFTR) and stimulates the secretion of
chloride and bicarbonate into the intestinal lumen. This promotes sodium excretion
into the lumen and results in increased intestinal fluid secretion. This ultimately
accelerates GI transit of intestinal contents, improves bowel movement and relieves
constipation. Increased extracellular cGMP levels may also exert an antinociceptive
effect, through an as of yet not fully elucidated mechanism, that may involve modulation
of nociceptors found on colonic afferent pain fibers. Linaclotide is minimally absorbed
from the GI tract.;
UNII : N0TXR0XR5X;
CAS number : 851199-59-2;
Drug name : Linzess;
Molecule name : MD-1100;
Chemical formula : C59H79N15O21S6;
PubMed : 19098860;
Origin ID : C81001;
UMLS CUI : C2000261;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_salt_form
- is_free_acid_or_base_form_of
